Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 59 entries
Sorted by: Best Match Show Resources per page
Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes.

Journal of the Endocrine Society

Rajpal A, Kassem LS, Moscoso-Cordero M, Arafah BM.
PMID: 29264578
J Endocr Soc. 2017 Aug 28;1(9):1217-1223. doi: 10.1210/js.2017-00316. eCollection 2017 Sep 01.

Insulin autoimmune syndrome (IAS), defined as hyperinsulinemic hypoglycemia with high titers of anti-insulin antibodies, is frequently reported in Japanese patients but rarely observed in whites. We report in this study on a 79-year-old white male without diabetes who developed...

Cite
Rajpal A, Kassem LS, Moscoso-Cordero M, et al. Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes. J Endocr Soc. 2017;1(9):1217-1223doi: 10.1210/js.2017-00316.
Rajpal, A., Kassem, L. S., Moscoso-Cordero, M., & Arafah, B. M. (2017). Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes. Journal of the Endocrine Society, 1(9), 1217-1223. https://doi.org/10.1210/js.2017-00316
Rajpal, Aman, et al. "Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes." Journal of the Endocrine Society vol. 1,9 (2017): 1217-1223. doi: https://doi.org/10.1210/js.2017-00316
Rajpal A, Kassem LS, Moscoso-Cordero M, Arafah BM. Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes. J Endocr Soc. 2017 Aug 28;1(9):1217-1223. doi: 10.1210/js.2017-00316. eCollection 2017 Sep 01. PMID: 29264578; PMCID: PMC5686698.
Copy Download .nbib Format: NLM
ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and Adolescents.

Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH

Delic-Sarac M, Mutevelic S, Karamehic J, Subasic D, Jukic T, Coric J, Ridjic O, Panjeta M, Zunic L.
PMID: 27041813
Acta Inform Med. 2016 Feb;24(1):61-5. doi: 10.5455/aim.2016.24.61-65. Epub 2016 Feb 02.

INTRODUCTION: Anti GAD (antibodies on glutamic acid decarboxylase) and anti-IA2 antibodies (against tyrosine phosphatase), today, have their place and importance in diagnosis and prognosis of Type 1 diabetes. Huge number of patients with diabetes mellitus type 1 have these...

Cite
Delic-Sarac M, Mutevelic S, Karamehic J, et al. ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and Adolescents. Acta Inform Med. 2016;24(1):61-5doi: 10.5455/aim.2016.24.61-65.
Delic-Sarac, M., Mutevelic, S., Karamehic, J., Subasic, D., Jukic, T., Coric, J., Ridjic, O., Panjeta, M., & Zunic, L. (2016). ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and Adolescents. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH, 24(1), 61-5. https://doi.org/10.5455/aim.2016.24.61-65
Delic-Sarac, Marina, et al. "ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and Adolescents." Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH vol. 24,1 (2016): 61-5. doi: https://doi.org/10.5455/aim.2016.24.61-65
Delic-Sarac M, Mutevelic S, Karamehic J, Subasic D, Jukic T, Coric J, Ridjic O, Panjeta M, Zunic L. ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and Adolescents. Acta Inform Med. 2016 Feb;24(1):61-5. doi: 10.5455/aim.2016.24.61-65. Epub 2016 Feb 02. PMID: 27041813; PMCID: PMC4789625.
Copy Download .nbib Format: NLM
Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature.

Case reports in endocrinology

Rao BB, Click B, Eid G, Codario RA.
PMID: 26523235
Case Rep Endocrinol. 2015;2015:384526. doi: 10.1155/2015/384526. Epub 2015 Oct 07.

Background. Roux-en-Y gastric bypass (RYGB) is a commonly performed, effective bariatric procedure; however, rarely, complications such as postprandial hypoglycemia due to noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) may ensue. Management of refractory NIPHS is challenging. We report a case that...

Cite
Rao BB, Click B, Eid G, et al. Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature. Case Rep Endocrinol. 2015;2015:384526doi: 10.1155/2015/384526.
Rao, B. B., Click, B., Eid, G., & Codario, R. A. (2015). Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature. Case reports in endocrinology, 2015384526. https://doi.org/10.1155/2015/384526
Rao, Bhavana B, et al. "Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature." Case reports in endocrinology vol. 2015 (2015): 384526. doi: https://doi.org/10.1155/2015/384526
Rao BB, Click B, Eid G, Codario RA. Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature. Case Rep Endocrinol. 2015;2015:384526. doi: 10.1155/2015/384526. Epub 2015 Oct 07. PMID: 26523235; PMCID: PMC4617428.
Copy Download .nbib Format: NLM
Similar Efficacy and Safety of Basaglar.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Pollom RK, Costigan T, Lacaya LB, Ilag LL, Hollander PA.
PMID: 29542012
Diabetes Ther. 2018 Apr;9(2):827-837. doi: 10.1007/s13300-018-0405-5. Epub 2018 Mar 14.

INTRODUCTION: To compare efficacy and safety of BasaglarMETHODS: This subgroup analysis of a phase 3, randomized, double-blind, multinational, 24-week study compared LY IGlar and SA IGlar on several clinical efficacy (change in glycated hemoglobin (A1c), basal insulin dose, weight)...

Cite
Pollom RK, Costigan T, Lacaya LB, et al. Similar Efficacy and Safety of Basaglar. Diabetes Ther. 2018;9(2):827-837doi: 10.1007/s13300-018-0405-5.
Pollom, R. K., Costigan, T., Lacaya, L. B., Ilag, L. L., & Hollander, P. A. (2018). Similar Efficacy and Safety of Basaglar. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(2), 827-837. https://doi.org/10.1007/s13300-018-0405-5
Pollom, Robyn K, et al. "Similar Efficacy and Safety of Basaglar." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 9,2 (2018): 827-837. doi: https://doi.org/10.1007/s13300-018-0405-5
Pollom RK, Costigan T, Lacaya LB, Ilag LL, Hollander PA. Similar Efficacy and Safety of Basaglar. Diabetes Ther. 2018 Apr;9(2):827-837. doi: 10.1007/s13300-018-0405-5. Epub 2018 Mar 14. PMID: 29542012; PMCID: PMC6104266.
Copy Download .nbib Format: NLM
The inactivation of the biological properties of insulin by 131 I labelling or irradation.

Diabetologia

Pellegrini G, Maggi G, Rodari T, Specchia G.
PMID: 24173308
Diabetologia. 1966 Apr;1(3):242-4. doi: 10.1007/BF01257918.

The various biological properties of crystalline insulin labelled with(131)I and crystalline insulin submitted to irradiation were studied. The properties investigated were the hypoglycemie, convulsive and antigenic activities, and the effect on the glucose uptake of the diaphragm and the...

Cite
Pellegrini G, Maggi G, Rodari T, et al. The inactivation of the biological properties of insulin by 131 I labelling or irradation. Diabetologia. 1966;1(3):242-4doi: 10.1007/BF01257918.
Pellegrini, G., Maggi, G., Rodari, T., & Specchia, G. (1966). The inactivation of the biological properties of insulin by 131 I labelling or irradation. Diabetologia, 1(3), 242-4. https://doi.org/10.1007/BF01257918
Pellegrini, G, et al. "The inactivation of the biological properties of insulin by 131 I labelling or irradation." Diabetologia vol. 1,3 (1966): 242-4. doi: https://doi.org/10.1007/BF01257918
Pellegrini G, Maggi G, Rodari T, Specchia G. The inactivation of the biological properties of insulin by 131 I labelling or irradation. Diabetologia. 1966 Apr;1(3):242-4. doi: 10.1007/BF01257918. PMID: 24173308.
Copy Download .nbib Format: NLM
Insulin treatment and development of anti-insulin antibodies in a horse with diabetes mellitus associated with a functional pituitary adenoma.

The Canadian veterinary journal = La revue veterinaire canadienne

Staempfli HR, Eigenmann EJ, Clarke LM.
PMID: 17423172
Can Vet J. 1988 Nov;29(11):934-6.

No abstract available.

Cite
Staempfli HR, Eigenmann EJ, Clarke LM. Insulin treatment and development of anti-insulin antibodies in a horse with diabetes mellitus associated with a functional pituitary adenoma. Can Vet J. 1988;29(11):934-6
Staempfli, H. R., Eigenmann, E. J., & Clarke, L. M. (1988). Insulin treatment and development of anti-insulin antibodies in a horse with diabetes mellitus associated with a functional pituitary adenoma. The Canadian veterinary journal = La revue veterinaire canadienne, 29(11), 934-6.
Staempfli, H R, et al. "Insulin treatment and development of anti-insulin antibodies in a horse with diabetes mellitus associated with a functional pituitary adenoma." The Canadian veterinary journal = La revue veterinaire canadienne vol. 29,11 (1988): 934-6.
Staempfli HR, Eigenmann EJ, Clarke LM. Insulin treatment and development of anti-insulin antibodies in a horse with diabetes mellitus associated with a functional pituitary adenoma. Can Vet J. 1988 Nov;29(11):934-6. PMID: 17423172; PMCID: PMC1680938.
Copy Download .nbib Format: NLM
Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP).

ACS central science

Tsai CT, Robinson PV, Spencer CA, Bertozzi CR.
PMID: 27064772
ACS Cent Sci. 2016 Mar 23;2(3):139-147. doi: 10.1021/acscentsci.5b00340. Epub 2016 Feb 16.

Antibodies are widely used biomarkers for the diagnosis of many diseases. Assays based on solid-phase immobilization of antigens comprise the majority of clinical platforms for antibody detection, but can be undermined by antigen denaturation and epitope masking. These technological...

Cite
Tsai CT, Robinson PV, Spencer CA, et al. Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP). ACS Cent Sci. 2016;2(3):139-147doi: 10.1021/acscentsci.5b00340.
Tsai, C. T., Robinson, P. V., Spencer, C. A., & Bertozzi, C. R. (2016). Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP). ACS central science, 2(3), 139-147. https://doi.org/10.1021/acscentsci.5b00340
Tsai, Cheng-Ting, et al. "Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP)." ACS central science vol. 2,3 (2016): 139-147. doi: https://doi.org/10.1021/acscentsci.5b00340
Tsai CT, Robinson PV, Spencer CA, Bertozzi CR. Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP). ACS Cent Sci. 2016 Mar 23;2(3):139-147. doi: 10.1021/acscentsci.5b00340. Epub 2016 Feb 16. PMID: 27064772; PMCID: PMC4819452.
Copy Download .nbib Format: NLM
Improvement of Glucose Control and Reduction of Hypoglycemia Following Intravenous Immune Globulins in a Child With Type 1 Diabetes and High Levels of Insulin Antibodies.

Diabetes care

Marchand L, Luigi P, Place J, Dalla-Vale F, Farret A, Renard E.
PMID: 28385685
Diabetes Care. 2017 Jun;40(6):e69-e70. doi: 10.2337/dc16-2420. Epub 2017 Apr 06.

No abstract available.

Cite
Marchand L, Luigi P, Place J, et al. Improvement of Glucose Control and Reduction of Hypoglycemia Following Intravenous Immune Globulins in a Child With Type 1 Diabetes and High Levels of Insulin Antibodies. Diabetes Care. 2017;40(6):e69-e70doi: 10.2337/dc16-2420.
Marchand, L., Luigi, P., Place, J., Dalla-Vale, F., Farret, A., & Renard, E. (2017). Improvement of Glucose Control and Reduction of Hypoglycemia Following Intravenous Immune Globulins in a Child With Type 1 Diabetes and High Levels of Insulin Antibodies. Diabetes care, 40(6), e69-e70. https://doi.org/10.2337/dc16-2420
Marchand, Lucien, et al. "Improvement of Glucose Control and Reduction of Hypoglycemia Following Intravenous Immune Globulins in a Child With Type 1 Diabetes and High Levels of Insulin Antibodies." Diabetes care vol. 40,6 (2017): e69-e70. doi: https://doi.org/10.2337/dc16-2420
Marchand L, Luigi P, Place J, Dalla-Vale F, Farret A, Renard E. Improvement of Glucose Control and Reduction of Hypoglycemia Following Intravenous Immune Globulins in a Child With Type 1 Diabetes and High Levels of Insulin Antibodies. Diabetes Care. 2017 Jun;40(6):e69-e70. doi: 10.2337/dc16-2420. Epub 2017 Apr 06. PMID: 28385685.
Copy Download .nbib Format: NLM
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients.

Diabetology & metabolic syndrome

Li Z, Yi D, Zheng L, Li S, Fang W, Wang C.
PMID: 33827670
Diabetol Metab Syndr. 2021 Apr 07;13(1):38. doi: 10.1186/s13098-021-00658-z.

BACKGROUND: The exact incidence, clinical features and uniform diagnostic criteria of exogenous insulin autoimmune syndrome (EIAS) are still unclear. The purpose of this study is to explore the clinical characteristics of EIAS and to provide a structural approach for...

Cite
Li Z, Yi D, Zheng L, et al. Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients. Diabetol Metab Syndr. 2021;13(1):38doi: 10.1186/s13098-021-00658-z.
Li, Z., Yi, D., Zheng, L., Li, S., Fang, W., & Wang, C. (2021). Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients. Diabetology & metabolic syndrome, 13(1), 38. https://doi.org/10.1186/s13098-021-00658-z
Li, Zuojun, et al. "Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients." Diabetology & metabolic syndrome vol. 13,1 (2021): 38. doi: https://doi.org/10.1186/s13098-021-00658-z
Li Z, Yi D, Zheng L, Li S, Fang W, Wang C. Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients. Diabetol Metab Syndr. 2021 Apr 07;13(1):38. doi: 10.1186/s13098-021-00658-z. PMID: 33827670; PMCID: PMC8028117.
Copy Download .nbib Format: NLM
Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Jerkins T, Bell DSH.
PMID: 34403116
Diabetes Ther. 2021 Oct;12(10):2795-2799. doi: 10.1007/s13300-021-01129-4. Epub 2021 Aug 17.

Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hyperglycemia, ketosis, ketoacidosis, and hypoglycemia when insulin is released from the saturated insulin antibodies. Recommended treatment regimens include glucocorticoids,...

Cite
Jerkins T, Bell DSH. Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes Ther. 2021;12(10):2795-2799doi: 10.1007/s13300-021-01129-4.
Jerkins, T., & Bell, D. S. H. (2021). Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(10), 2795-2799. https://doi.org/10.1007/s13300-021-01129-4
Jerkins, Terri, and Bell, David S H. "Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,10 (2021): 2795-2799. doi: https://doi.org/10.1007/s13300-021-01129-4
Jerkins T, Bell DSH. Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes Ther. 2021 Oct;12(10):2795-2799. doi: 10.1007/s13300-021-01129-4. Epub 2021 Aug 17. PMID: 34403116; PMCID: PMC8479014.
Copy Download .nbib Format: NLM
A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma.

AACE clinical case reports

Chae K, Perlman J, Fransman RB, Wolfgang CL, De Jesus-Acosta A, Mathioudakis N.
PMID: 34765736
AACE Clin Case Rep. 2021 Jun 11;7(6):379-382. doi: 10.1016/j.aace.2021.06.001. eCollection 2021.

OBJECTIVE: We describe a rare case of profound subcutaneous insulin resistance (SIR) presumed due to a paraneoplastic process caused by pancreatic adenocarcinoma that improved with intravenous insulin and tumor resection.METHODS: An 80-year-old man with previously well-controlled type 2 diabetes...

Cite
Chae K, Perlman J, Fransman RB, et al. A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma. AACE Clin Case Rep. 2021;7(6):379-382doi: 10.1016/j.aace.2021.06.001.
Chae, K., Perlman, J., Fransman, R. B., Wolfgang, C. L., De Jesus-Acosta, A., & Mathioudakis, N. (2021). A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma. AACE clinical case reports, 7(6), 379-382. https://doi.org/10.1016/j.aace.2021.06.001
Chae, Kacey, et al. "A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma." AACE clinical case reports vol. 7,6 (2021): 379-382. doi: https://doi.org/10.1016/j.aace.2021.06.001
Chae K, Perlman J, Fransman RB, Wolfgang CL, De Jesus-Acosta A, Mathioudakis N. A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma. AACE Clin Case Rep. 2021 Jun 11;7(6):379-382. doi: 10.1016/j.aace.2021.06.001. eCollection 2021. PMID: 34765736; PMCID: PMC8573285.
Copy Download .nbib Format: NLM
Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog.

Endocrinology, diabetes & metabolism case reports

Su CT, Lin YC.
PMID: 27933175
Endocrinol Diabetes Metab Case Rep. 2016;2016. doi: 10.1530/EDM-16-0079. Epub 2016 Nov 17.

Insulin antibodies (IA) associated with exogenous insulin administration seldom caused hypoglycemia and had different characteristics from insulin autoantibodies (IAA) found in insulin autoimmune syndrome (IAS), which was first described by Dr Hirata in 1970. The characteristic of IAS is...

Cite
Su CT, Lin YC. Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinol Diabetes Metab Case Rep. 2016;2016doi: 10.1530/EDM-16-0079.
Su, C. T., & Lin, Y. C. (2016). Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinology, diabetes & metabolism case reports, 2016. https://doi.org/10.1530/EDM-16-0079
Su, Chih-Ting, and Lin, Yi-Chun. "Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog." Endocrinology, diabetes & metabolism case reports vol. 2016 (2016). doi: https://doi.org/10.1530/EDM-16-0079
Su CT, Lin YC. Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinol Diabetes Metab Case Rep. 2016;2016. doi: 10.1530/EDM-16-0079. Epub 2016 Nov 17. PMID: 27933175; PMCID: PMC5118974.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 59 entries